Holen Sie sich die Stockscreener-App
6.44
6.80%
-0.47
Handel nachbörslich:
6.44
Schlusskurs vom Vortag:
$6.91
Offen:
$6.89
24-Stunden-Volumen:
53,275
Relative Volume:
0.62
Marktkapitalisierung:
$682.86M
Einnahmen:
$117.05M
Nettoeinkommen (Verlust:
$-3.71M
KGV:
-82.67
EPS:
-0.0779
Netto-Cashflow:
$1.67M
1W Leistung:
-5.43%
1M Leistung:
+8.42%
6M Leistung:
-23.33%
1J Leistung:
-21.27%
1-Tages-Spanne:
$6.42
$6.89
1-Wochen-Bereich:
$6.42
$7.29
52-Wochen-Spanne:
$5.44
$9.42
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Firmenname
Gyre Therapeutics Inc
Sektor
Branche
Telefon
(858) 284-0115
Adresse
12730 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
6.44 | 744.36M | 117.05M | -3.71M | 1.67M | -0.0779 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | Jefferies | Buy |
| 2025-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-11 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
Gyre (GYRE) Results Review: The EPS Result Is Below Expectation in the Latest Session; After Results: Shares Move 1.82% Down for the Current SessionBalance Sheet Strength - vinanet.vn
Gyre (GYRE): Slides 2.10% to $7.00 in Latest Trading; Trading Range: Price Remains Between $6.65 Support and $7.35 ResistanceBackspread Trade - vinanet.vn
Gyre Therapeutics (NASDAQ:GYRE) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Analysts Set Expectations for GYRE Q3 Earnings - MarketBeat
GYRE | Gyre Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Claire Weston Net Worth (2026) - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN) - The Globe and Mail
Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Gyre Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gyre Therapeutics earnings missed by $0.06, revenue topped estimates - Investing.com Nigeria
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Lights a Fire Under SharesEarnings Surprise Score - vinanet.vn
Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results - MarketBeat
Form 8K Gyre Therapeutics Inc For: 7 August By Investing.com - Investing.com Nigeria
GYRE: Net loss widened to $32.8 million on $53.5 million revenue, with strong liquidity maintained - TradingView
Gyre Therapeutics (NASDAQ: GYRE) swings to 32,849 H1 2026 net loss - Stock Titan
Gyre Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Gyre Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gyre Therapeutics Q2 EPS misses estimate despite sales beat - scanx.trade
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Gyre Therapeutics Sees 2026 Rev $100.5M-$111.0M >GYRE - Moomoo
Gyre Therapeutics Reports Second Quarter 2026 - Moomoo
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
GYRE Q2 Revenue Falls To $29.1 Million As Net Loss Widens - Quiver Quantitative
GYRE: Q2 2026 revenue reached $29.1M, net loss widened, and Cullgen acquisition expanded the pipeline - TradingView
Gyre Therapeutics reports Q2 2026 revenue $29.1M, GAAP EPS $(0.12); full-year revenue guidance affirmed - TradingView
Gyre Therapeutics, Inc. Affirms Earnings Guidance for the Full Year of 2026 - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: A 191% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
L9S.DU interactive stock chart | Gyre Therapeutics Inc. R stock - Yahoo Finance Australia
Gyre Therapeutics, Inc. (GYRE) grants director options on 40,000 shares - Stock Titan
Gyre Therapeutics (GYRE) director discloses no stock ownership - Stock Titan
Gyre Therapeutics (GYRE) awards director 40,000 stock options vesting to 2029 - Stock Titan
Weston Claire files initial ownership report at Gyre Therapeutics (GYRE) - Stock Titan
Gyre Therapeutics director Kirkby Maxwell files initial beneficial ownership statement - Bitget
GYRE THERAPEUTICS, INC. SEC Filing (Aug 4, 2026) - Stock Titan
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Gyr - The National Law Review
Gyre Therapeutics (GYRE) to Post Quarterly Earnings on Monday - MarketBeat
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 39.84% as Shares Slip 1.03%CEO Earnings Statement - vinanet.vn
Gyre Therapeutics, Inc. (GYRE) Investor Outlook: Exploring a Promising 221% Upside in Biotech - DirectorsTalk Interviews
Gyre Therapeutics Inc (GYRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 5.8%Here's Why - MarketBeat
Gyre Therapeutics Inc (GYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gyre Therapeutics Inc (GYRE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gyre Therapeutics Inc (GYRE) Balance Sheet - TradingKey
Gyre Therapeutics Inc (GYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gyre Therapeutics Inc (GYRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gyre Therapeutics Inc (GYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GYRE|Gyre Therapeutics Inc|Price:6.110|Chg%:+0.170 - TradingKey
GYRE Q1 2026 Earnings: EPS Surprises to the Upside Despite Zero RevenueEarnings Surprise Score - vinanet.vn
Gyre Therapeutics Inc (GYRE) Income Statement - TradingKey
Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gyre Therapeutics Inc-Aktie (GYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Option Exercise |
0.75 |
3,000 |
2,250 |
703,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 18 '26 |
Option Exercise |
0.75 |
3,000 |
2,250 |
703,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 10 '26 |
Sale |
6.24 |
5,000 |
31,200 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 18 '26 |
Sale |
6.35 |
3,000 |
19,050 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Sale |
6.15 |
3,000 |
18,450 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 11 '26 |
Option Exercise |
0.75 |
2,800 |
2,100 |
702,800 |
| Ye Weiguo | Chief Operating Officer |
Jun 11 '26 |
Sale |
6.17 |
2,800 |
17,276 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Option Exercise |
0.75 |
14,500 |
10,875 |
714,500 |
| Ye Weiguo | Chief Operating Officer |
Jun 10 '26 |
Option Exercise |
0.75 |
6,418 |
4,814 |
706,418 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Sale |
6.14 |
14,500 |
89,030 |
700,000 |
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):